Serological and immunohistopathological studies on the effect of radiation on tumor-host relationship

1.辐射对荷瘤宿主免疫学影响的研究(1)血清SCC抗原水平的测定恶性肿瘤患者血清SCC水平阳性率为19%，各种非恶性疾病患者血清SCC水平阳性率为8%，健康对照组为0%。食道癌、宫颈癌、肺癌、皮肤癌和阴道癌患者血清SCC水平较高。根据组织学类型，分化型鳞癌产生的血清SCC抗原水平高于其他组织学类型。结论：1.放射治疗后血清鳞癌抗原水平升高迅速降至正常水平。免疫增强剂最佳给药方法的研究(1)放射治疗后口服PS-K 3.0g/d，每月2周，间歇给药。PS-K间歇给药是有效的，停药时间应在患者全身状况良好时的2个月内。(2)实验研究PS-K对小鼠淋巴组织最长时间的组织病理学影响以及与放射联合使用的影响。在网状内皮系统观察到明显的变化，表明PS-K的作用。随着网状内皮系统的激活，出现明显的无结构样半透明基质。用I-131标记的抗CEA和抗CA19-9单抗(IMACIS-1)评价免疫核素显像的研究86例患者中有66例(77%)显影阳性。阳性率与肿瘤大小显著相关。对荷人肺癌裸鼠注射IMACIS-1，获得阳性显像。

1. Studies on immunological changes by iiradiation in tumor-bearing hosts(1) Determinations of serum SCC antigen levelPositive rate of serum SCC level was 19% in patients with malignant tumors, 8% with various non-malignant diseases and 0% in healthy control. High serum levels of SCC were found in patients with esophageal cancer, cervical cancer, pulmonary cancer skin cancer and vaginal & vulval cancer. According to the histological types, differentiated squamous cell carcinoma appeard to produce a higher serum level of SCC antigen than other histological types. Elevated serum levels of SCC antigen rapidly decreased to a normal level after radio-therapy.2. Studies on the optimal administration method of an immunopotentiator(1) Clinical studiesPS-K was given orally 3.0g per day intermittently in the pattern of 2 weeks per month after radiation therapy. Intermittent administration of PS-K is effective and the period of withdrawal of the drug should be within 2 months when the patient is under good general condition.(2) Experimental studiesThe effects of PS-K on mice were studied histopathologically in lymphoid tissues in longest period and also when used with radiation. Distinctive changes which indicated the effects of PS-K were observed in reticuloendo-thelial system. Appearance of an obvious structureless-like translucentsub-stance followed the activation of the reticuloendothelial system.3. Studies on evaluation of immunoscintigraphy using I-131 labeled anti CEA and anti CA 19-9 monoclonal antibody(IMACIS 1)The positive scintigraphies were obtained in 66 of 86 cases(77%) clinically. There was significant correlation of positive ratio with tumor size.The nude mice that were bearing human lung cancer were recieved administration of IMACIS 1. Then the positive scintigraphies were obtained.